Artin Minaeian, MD
Neurology · Glendale, CANPI 1013356344
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $119,084 of the $171,884 with a category attached, or 69.3%. 60 manufacturers reported payments, led by Lilly USA, LLC at 28.4% of the total. 2025 is the largest year on record at $56,140, 5.1 times the $10,920 reported in 2019. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,457 payments — averaging $117.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$49K
- AbbVie$47K
- Eisai Inc.$18K
- Teva Pharmaceuticals USA, Inc.$16K
- TG Therapeutics, Inc.$11K
- EMD Serono, Inc.$4K
- plus $27K from 54 others
Across 127 payments — averaging $14,700 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$483K
- Novartis$443K
- UCB SA$326K
- Genentech, Inc.$289K
- TG Therapeutics, Inc.$257K
- AbbVie$45K
- plus $25K from 4 others
What the payments were for
- Consulting fees$14,4808%
- Speaking & faculty fees$119,08469%
- Travel & lodging$5,4243%
- Food & beverage$32,22219%
- Education$6740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$41,775
- KISUNLA$17,425
- Leqembi$16,847
- AJOVY$14,442
- QULIPTA$12,084
- BRIUMVI$9,894
- NURTEC ODT$3,911
- LINQ II$394
- XARELTO$231
- Mavenclad$222
- Watchman$173
- ZOOM 88-T LARGE DISTAL PLATFORM$163
- VNS Therapy$129
- BRILINTA$125
- Viz.AI LVO$125
- KESIMPTA$122
- MAYZENT$122
- Repatha$121
- VYVGART$120
- XCOPRI$119
How this compares
$171,884 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 44 | $209,314 |
| BotoxOnabotulinumtoxina | 110 | $151,108 |
| AubagioTeriflunomide | 14 | $128,839 |
| VumerityDiroximel Fumarate | 12 | $99,215 |
| UbrelvyUbrogepant | 72 | $97,906 |
| ZeposiaOzanimod Hydrochloride | 11 | $91,471 |
| QuliptaAtogepant | 51 | $61,709 |
| NuplazidPimavanserin Tartrate | 12 | $61,135 |
| RexultiBrexpiprazole | 32 | $45,300 |
| Nurtec OdtRimegepant Sulfate | 41 | $42,971 |
| GocovriAmantadine Hcl | 17 | $27,230 |
| Aimovig AutoinjectorErenumab-Aooe | 33 | $24,472 |
| BriviactBrivaracetam | 17 | $22,370 |
| RytaryCarbidopa/Levodopa | 37 | $21,136 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 19 | $18,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy, Qulipta, Namzaric | $46,519 | $326,881245 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $89 | $209,31444 claims |
| SanofiAubagio | $326 | $128,83914 claims |
| BiogenVumerity | $1,569 | $99,21512 claims |
| Acadia Pharmaceuticals IncNuplazid | $714 | $61,13512 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $310 | $45,30032 claims |
| PfizerNurtec Odt | $589 | $42,97141 claims |
| UCB, Inc.Briviact, Neupro | $1,629 | $31,60928 claims |
| MDD US Operations, LLCGocovri | $433 | $27,23017 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $608 | $22,98771 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $243 | $3,95712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.
Other neurology in Glendale
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.